Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1.639 artigos
Paris-based Lucis uses AI and blood biomarker panels to flag sub-clinical risks early, with 75% of users improving key markers in six months.
Sam Altman-backed Retro Biosciences hits $1.8B valuation as its first human trial targeting Alzheimer's protein buildup shows early promise.
Daewoong Pharmaceutical buys Turn Bio's ERA platform, using mRNA to partially reverse cellular aging without tumor risk.
Industry leaders at Milan 2026 say longevity medicine must move beyond hype and deliver measurable, accountable preventive care.
UC Berkeley researchers expose critical incoherence in DNA methylation age clocks, showing up to 54% of their features contradict actual biological trends.
First RCT evidence that semaglutide significantly reduces epigenetic age across multiple validated clocks in people with HIV-associated lipohypertrophy.
A 234-patient study shows lecanemab is feasible in specialty clinics, with ARIA occurring in 22% but severe events in only 1% of patients.
Scientists identify MRAP as a key molecular driver of thymic fat replacement, linking thymosin-α1 and FoxO1 signaling to immune aging.
Dendrobium officinale extract protects aging kidneys by activating antioxidant defenses through a key cellular signaling pathway.
A deubiquitinase stabilizes a key chaperone protein to activate protective autophagy and block iron-driven cell death in spinal discs.
Scientists discover PRDM16 declines in aged organs and its loss accelerates senescence; restoring it via GSTM1 may slow organ aging.
New research reveals omega-3s activate a receptor that curbs cellular senescence and fibrosis in kidneys, pointing to a clear biological mechanism.
